Table 2.
ISCL/EORTC revision of mycosis fungoides and Sézary syndrome staging4
| T | N | M | B | |
|---|---|---|---|---|
|
| ||||
| IA | 1 | 0 | 0 | 0, 1 |
| IB | 2 | 0 | 0 | 0, 1 |
| IIA | 1, 2 | 1, 2 | 0 | 0, 1 |
| IIBa | 3 | 0–2 | 0 | 0, 1 |
| IIIa | 4 | 0–2 | 0 | 0, 1 |
| IIIAa | 4 | 0–2 | 0 | 0 |
| IIIBa | 4 | 0–2 | 0 | 1 |
| IVA1a | 1–4 | 0–2 | 0 | 2 |
| IVA2a | 1–4 | 3 | 0 | 0–2 |
| IVBa | 1–4 | 0–3 | 1 | 0–2 |
Note:
a
Considered advanced-stage disease. Republished with permission of American Society of Hematology, from Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), Olsen E, et al, 110, 6, 2007; permission conveyed through Copyright Clearance Center, Inc.
Abbreviations: ISCL, International Society for Cutaneous Lymphomas; EORTC, European Organization for Research and Treatment of Cancer;